



Exploration of Medicine aims to disseminate our quality articles freely and widely and expand the impact of EM publications. Hence we are glad to share this EM Article List and hope they will be useful for your research or papers. Your reading, citing, and kind sharing it among your friends and colleagues are highly appreciated.

Welcome your submission with Free Charges & Scopus Indexing:

<https://mc03.manuscriptcentral.com/emed>

Editorial Office: emjournal@explorationpub.com

Twitter: @Explor_Med

LinkedIn: <https://www.linkedin.com/company/exploration-of-medicine/>



Content

Highlighted Articles	1
Cancer Biology & Oncology	2
Cardiovascular Medicine & Hematology	3
Endocrinology & Metabolism	5
Gastroenterology & Hepatology	7
Genetics & Genome Biology, Computational Biomedicine	10
Microbiology, Immunology & Infectious Disease	12
Neuroscience & Neuropsychiatric Disorders	13
Urology & Nephrology	14
Women's Health	16
Others	16

Highlighted Articles

[Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin](#)

Carlo Acierno, Alfredo Caturano, Pia Clara Pafundi, Riccardo Nevola, Luigi Elio Adinolfi, Ferdinando Carlo Sasso

[PDF](#)

[PNPLA3 gene and kidney disease](#)

Alessandro Mantovani, Chiara Zusi

[PDF](#)

[Sex differences in non-alcoholic fatty liver disease: hints for future management of the disease](#)

Noel C. Salvoza, Pablo J. Giraudi, Claudio Tiribelli, Natalia Rosso

[PDF](#)

[Nonalcoholic fatty liver disease and portal hypertension](#)

Marvin Ryou, Nicholas Stylopoulos, Gyorgy Baffy

[PDF](#)

[Perspectives of nonalcoholic fatty liver disease research: a personal point of view](#)

Amedeo Lonardo, Stefano Ballestri

[PDF](#)

[Identification of digital voice biomarkers for cognitive health](#)



Honghuang Lin, Cody Karjadi, Ting F. A. Ang, Joshi Prajakta, Chelsea McManus, Tuka W. Alhanai, James Glass, Rhoda Au

[PDF](#)

[Hyperuricemia—a serious complication among patients with chronic kidney disease: a systematic review and meta-analysis](#)

Ishfaq Rashid, Pooja Katravath, Pramil Tiwari, Sanjay D'Cruz, Shivani Jaswal, Gautam Sahu


[PDF](#)



[Current evidence and outcomes for retinopathy of prematurity prevention: insights into novel maternal and placental disease contributions](#)

Lara Carroll, Leah A. Owen

[PDF](#)



Cancer Biology & Oncology


Featured

Top Download

[Reactive oxygen species may influence on the crossroads of stemness, senescence, and carcinogenesis in a cell via the roles of APRO family proteins](#)

Yuka Ikeda, Kurumi Taniguchi, Nozomi Nagase, Ai Tsuji, Yasuko Kitagishi, Satoru Matsuda

[PDF](#) Download: 655



Editor's Pick

[Cell-derived vesicles for delivery of cancer immunotherapy](#)

Jialu Xu, Chao Wang

[PDF](#)

Latest Research (12 Articles)

- Giordano G, Martin-Willett R, Gibson LP, Camidge DR, Bowles DW, Hutchison KE, et al. Cannabis use in cancer patients: acute and sustained associations with pain, cognition, and quality of life. *Explor Med.* 2023;4:254-71. <https://doi.org/10.37349/emed.2023.00138> [\[PDF\]](#)
- Ali R, Virendra SA, Chawla PA. The journey of dostarlimab: a successful weapon for cancer treatment. *Explor Med.* 2022;3:592-606. <https://doi.org/10.37349/emed.2022.00116> [\[PDF\]](#)
- Minocha N, Saini S, Pandey P. Nutritional prospects of wheatgrass (*Triticum aestivum*) and its effects in treatment and chemoprevention. *Explor Med.* 2022;3:432-42. <https://doi.org/10.37349/emed.2022.00104> [\[PDF\]](#)
- Wang T, Xu H. Multi-faced roles of reactive oxygen species in anti-tumor T cell immune responses and combination immunotherapy. *Explor Med.* 2022;3:77-98. <https://doi.org/10.37349/emed.2022.00076> [\[PDF\]](#)
- Singh R, Manna PP. Reactive oxygen species in cancer progression and its role in therapeutics. *Explor Med.* 2022;3:43-57.

- <https://doi.org/10.37349/emed.2022.00073> [PDF]
6. Singh P, Yadav M, Niveria K, Verma AK. Nano-immunotherapeutics: targeting approach as strategic regulation at TME for cancer treatment. *Explor Med.* 2022;3:22–42.
<https://doi.org/10.37349/emed.2022.00072> [PDF]
 7. Li Z, Zhou X, Cai S, Fan J, Wei Z, Chen Y, et al. Key roles of CCCTC-binding factor in cancer evolution and development. *Explor Med.* 2021;2:516–26.
<https://doi.org/10.37349/emed.2021.00068> [PDF]
 8. Ikeda Y, Taniguchi K, Nagase N, Tsuji A, Kitagishi Y, Matsuda S. Reactive oxygen species may influence on the crossroads of stemness, senescence, and carcinogenesis in a cell via the roles of APRO family proteins. *Explor Med.* 2021;2:443–54.
<https://doi.org/10.37349/emed.2021.00062> [PDF]
 9. Ram Kumar Pandian S, Rencilin CF, Sundar K. Emerging nanomaterials for cancer immunotherapy. *Explor Med.* 2021;2:208–31.
<https://doi.org/10.37349/emed.2021.00043> [PDF]
 10. Paus C, van der Voort R, Cambi A. Nanomedicine in cancer therapy: promises and hurdles of polymeric nanoparticles. *Explor Med.* 2021;2:167–85.
<https://doi.org/10.37349/emed.2021.00040> [PDF]
 11. Safarzadeh Kozani P, Safarzadeh Kozani P, Malik MT. AS1411-functionalized delivery nanosystems for targeted cancer therapy. *Explor Med.* 2021;2:146–66.
<https://doi.org/10.37349/emed.2021.00039> [PDF]
 12. Xu J, Wang C. Cell-derived vesicles for delivery of cancer immunotherapy. *Explor Med.* 2021;2:39–59.
<https://doi.org/10.37349/emed.2021.00031> [PDF]

Cardiovascular Medicine & Hematology

Featured

Top Download

[High salt induced augmentation of angiotensin II mediated hypertension is associated with differential expression of tumor necrosis factor-alpha receptors in the kidney](#)

Dewan S. A. Majid, Alexander Castillo, Minolfa C. Prieto, L. Gabriel Navar

[PDF](#)


Rising Star

[Reactive oxygen species in cardiovascular diseases: an update](#)

Juanjuan Fei, Laurie J. Demillard, Jun Ren

[PDF](#)

Experimental Protocol




Editor's Pick

[Development of systolic dysfunction unrelated to myocardial infarction in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study](#)

Marcello Chinali, Gerard P. Aurigemma, Eva Gerdt, Kristian Wachtell, Peter M. Okin, Anujan Muthiah, Sverre E. Kjeldsen, Stevo Julius, Giovanni de Simone, Richard B. Devereux

[PDF](#)



Latest Research (19 Articles)

1. Rabkin SW. Assessing cardiac contractility in hypertension with heart failure with preserved ejection fraction: the value of left ventricular strain. *Explor Med.* 2023;4:115-26. <https://doi.org/10.37349/emed.2023.00128> [\[PDF\]](#)
2. Makani S, Laarje A, Mabrouk M, Zaid Y, Chahid M, Hifdi Z, et al. Right atrial thrombus, junctional tachycardia, and critical lower limb ischemia: three rare complications of severe acute respiratory syndrome coronavirus 2 infection. *Explor Med.* 2022;3:583–91. <https://doi.org/10.37349/emed.2022.00115> [\[PDF\]](#)
3. Ho CLB, Reid CM. Update on trials examining effects of night-time blood pressure lowering drug treatment on prevention of cardiovascular disease. *Explor Med.* 2022;3:461–7. <https://doi.org/10.37349/emed.2022.00107> [\[PDF\]](#)
4. Szczepańska-Sadowska E, Żera T. Vasopressin: a possible link between hypoxia and hypertension. *Explor Med.* 2022;3:414–31. <https://doi.org/10.37349/emed.2022.00103> [\[PDF\]](#)
5. Majid DSA, Castillo A, Prieto MC, Navar LG. High salt induced augmentation of angiotensin II mediated hypertension is associated with differential expression of tumor necrosis factor-alpha receptors in the kidney. *Explor Med.* 2022;3:205–18. <https://doi.org/10.37349/emed.2022.00086> [\[PDF\]](#)
6. Fei J, Demillard LJ, Ren J. Reactive oxygen species in cardiovascular diseases: an update. *Explor Med.* 2022;3:188–204. <https://doi.org/10.37349/emed.2022.00085> [\[PDF\]](#)
7. Chinali M, Aurigemma GP, Gerdt E, Wachtell K, Okin PM, Muthiah A, et al. Development of systolic dysfunction unrelated to myocardial infarction in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study. *Explor Med.* 2022;3:160–72. <https://doi.org/10.37349/emed.2022.00082> [\[PDF\]](#)
8. Bang CN, Li Z, Stokke IM, Kjeldsen SE, Julius S, Hille DA, et al. Incident left bundle branch block predicts cardiovascular events and death in hypertensive patients with left ventricular hypertrophy. The LIFE Study. *Explor Med.* 2022;3:149–59. <https://doi.org/10.37349/emed.2022.00081> [\[PDF\]](#)
9. Bang CN, Greve AM, Køber L, Muthiah A, Kjeldsen SE, Julius S, et al. Incident atrial fibrillation and heart failure in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study. *Explor Med.* 2022;3:139–48. <https://doi.org/10.37349/emed.2022.00080> [\[PDF\]](#)

10. Zacks ES, Stokke IM, Wachtell K, Hille DA, Høieggen A, Kjeldsen SE, et al. Time-varying serum uric acid predicts new-onset atrial fibrillation in treated hypertensive patients. The LIFE Study. *Explor Med*. 2022;3:128–38.
<https://doi.org/10.37349/emed.2022.00079> [PDF]
11. Radovanovic J, Banjac K, Obradovic M, Isenovic ER. Antioxidant enzymes and vascular diseases. *Explor Med*. 2021;2:544–55.
<https://doi.org/10.37349/emed.2021.00070> [PDF]
12. Rajasekaran P, Gandhi P, Idhrees M, Velayudhan BV. Aortic complications in pregnancy: the less remembered chapter—a narrative review. *Explor Med*. 2021;2:423–34.
<https://doi.org/10.37349/emed.2021.00060> [PDF]
13. Karabulut K, Kapici A, Andronikashvili A, Morgan J. A review of aortic thrombosis in COVID-19 infection. *Explor Med*. 2021;2:410–22.
<https://doi.org/10.37349/emed.2021.00059> [PDF]
14. Bhullar SK, Shah AK, Dhalla NS. Role of angiotensin II in the development of subcellular remodeling in heart failure. *Explor Med*. 2021;2:352–71.
<https://doi.org/10.37349/emed.2021.00054> [PDF]
15. Kelly AM. Why the aortic dissection detection risk score is problematic in emergency departments. *Explor Med*. 2021;2:348–51.
<https://doi.org/10.37349/emed.2021.00053> [PDF]
16. Tyberg JV. Wave propagation and reflection in the aorta and implications of the aortic windkessel. *Explor Med*. 2021;2:198–207.
<https://doi.org/10.37349/emed.2021.00042> [PDF]
17. Kajuluri LP, Singh K, Morgan KG. Vascular aging, the vascular cytoskeleton and aortic stiffness. *Explor Med*. 2021;2:186–97.
<https://doi.org/10.37349/emed.2021.00041> [PDF]
18. Han Z, Shaligram S, Faughnan ME, Clark D, Sun Z, Su H. Reduction of endoglin receptor impairs mononuclear cell-migration. *Explor Med*. 2020;1:136–48.
<https://doi.org/10.37349/emed.2020.00010> [PDF]
19. Antohi EL, Chioncel C. Understanding the cardiac systolic performance beyond left ventricular ejection fraction. *Explor Med*. 2020;1:75–84.
<https://doi.org/10.37349/emed.2020.00006> [PDF]

Endocrinology & Metabolism


Featured

Top Download

[Semaglutide: a game changer for metabolic diseases?](#)

Agostino Milluzzo, Lucia Manuella, Laura Sciacca

[PDF](#)



Top Read

[Oxidative stress in obesity and insulin resistance](#)

Anastasija Panic, Julijana Stanimirovic, Emina Sudar-Milovanovic, Esma R. Isenovic

[PDF](#)

Editor's Pick

[Silent coronary artery disease in type 2 diabetes: a narrative review on epidemiology, risk factors, and clinical studies](#)

Saula Vigili de Kreutzenberg

[PDF](#)




Table 1.
Main non-invasive tests for the screening of silent CAD

Test	Type	Advantages	Disadvantages
Exercise stress test	Functional	Low cost Physiologic stress	Low sensitivity
Stress echocardiography	Functional	Low cost Pharmacological/physiological stress High specificity	Difficult in some patients False negative if single vessel disease
Radionuclide imaging	Functional	High sensitivity	Radiation False positive
Coronary artery calcium	Anatomic	Non-invasive	Radiation No stenosis evaluation
Coronary computed tomography angiography	Anatomic	High negative predictive value	No function evaluation
Magnetic resonance imaging	Anatomic/functional	Expensive	Preliminary studies

Latest Research (13 Articles)

- Kupek E. Can we estimate the causal effects of diet and sedentary behavior on schoolchildren's overweight/obesity from observational studies? *Explor Med.* 2023;4:272 – 85.
<https://doi.org/10.37349/emed.2023.00139> [\[PDF\]](#)
- Law VYH, Young JHM, Ng HY, Chan LTW. Abnormal glucose tolerance in children: oral glucose tolerance test is fit-for-purpose. *Explor Med.* 2023;4:235 – 45.
<https://doi.org/10.37349/emed.2023.00136> [\[PDF\]](#)
- Sonoli SS, Kothiwale VA, Channashetti RD. Alterations in metabolic status of healthy individuals with and without obesity during transition from adolescence and young adulthood. *Explor Med.* 2023;4:3 – 15.
<https://doi.org/10.37349/emed.2023.00120> [\[PDF\]](#)
- Mishra C, Ailani V, Saxena D, Yadav YK, Singh S, Kumar V, et al. Is there any correlation between muscle fatigue and serum lactate dehydrogenase levels in prediabetic individuals? *Explor Med.* 2022;3:368–74.
<https://doi.org/10.37349/emed.2022.00099> [\[PDF\]](#)
- Milluzzo A, Manuella L, Sciacca L. Semaglutide: a game changer for metabolic diseases? *Explor Med.* 2022;3:173–80.
<https://doi.org/10.37349/emed.2022.00083> [\[PDF\]](#)
- Panic A, Stanimirovic J, Sudar-Milovanovic E, Isenovic ER. Oxidative stress in obesity and insulin resistance. *Explor Med.* 2022;3:58–70.
<https://doi.org/10.37349/emed.2022.00074> [\[PDF\]](#)
- Maurantonio M, Gabrielli F, Castellano C, Carla A, Andreone P, Roncucci L. Risk factors in acute diabetic foot syndrome: analysis of 75 consecutive patients referred to a tertiary center in Modena, Italy. *Explor Med.* 2021;2:98–109.
<https://doi.org/10.37349/emed.2021.00035> [\[PDF\]](#)
- Vigili de Kreutzenberg S. Silent coronary artery disease in type 2 diabetes: a narrative review on epidemiology, risk factors, and clinical studies. *Explor Med.* 2021;2:1–19.
<https://doi.org/10.37349/emed.2021.00029> [\[PDF\]](#)
- Malaguarnera R, Scamporrino A, Filippello A, Di Mauro S, Minardo A, Purrello F, et al. The entero-insular axis: a journey in the physiopathology of diabetes. *Explor Med.* 2020;1:364–76.

<https://doi.org/10.37349/emed.2020.00025>

[PDF]

10. Pedone E, Laurenzi A, Allora A, Bolla AM, Caretto A. Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now? *Explor Med.* 2020;1:314–30.

<https://doi.org/10.37349/emed.2020.00021>

[PDF]

11. Mantovani A, Rinaldi E, Zusi C. Country rankings on the scientific production in endocrinology and diabetology. *Explor Med.* 2020;1:307–13.

<https://doi.org/10.37349/emed.2020.00020>

[PDF]

12. Milluzzo A, Vigneri P, Martorana F, Vigneri R, Sciacca L. Type 2 diabetes and cancer: problems and suggestions for best patient management. *Explor Med.* 2020;1:184–204.

<https://doi.org/10.37349/emed.2020.00013>

[PDF]

13. Mantovani A, Beatrice G, Petracca G, Pampagnin F, Sandri D, Targher G. GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis. *Explor Med.* 2020;1:108–23.

<https://doi.org/10.37349/emed.2020.00008>

[PDF]

Gastroenterology & Hepatology

Featured

Top Download

[Construction and validation of gastric cancer diagnosis model based on machine learning](#)

Fei Kong, Ziqin Yan, Ning Lan, Pinxiu Wang, Shanlin Fan, Wenzhen Yuan

[PDF](#)

Rising Star

[Pyogenic liver abscess: contrast-enhanced ultrasound allows morpho-evolutive classification and guides personalized management](#)

Giampiero Francica



[PDF](#)

Top Read

[Functions of two distinct Kupffer cells in the liver](#)

Chunye Zhang, Shuai Liu, Ming Yang

[PDF](#)



Editor's Pick

[Separating the apples from the oranges: from NAFLD heterogeneity to personalized medicine](#)

Amedeo Lonardo

[PDF](#)

Table 1
Summary of evidence of individual impact on precision medicine approaches to NAFLD

Approach	Impact	Ref.
Genetic	Identification of genetic variants and polymorphisms	123
Epigenetic	Identification of epigenetic markers and polymorphisms	124
Transcriptomic	Identification of transcriptomic markers and polymorphisms	125
Proteomic	Identification of proteomic markers and polymorphisms	126
Metabolic	Identification of metabolic markers and polymorphisms	127
Immunologic	Identification of immunologic markers and polymorphisms	128
Microbiomic	Identification of microbiomic markers and polymorphisms	129
Environmental	Identification of environmental markers and polymorphisms	130
Behavioral	Identification of behavioral markers and polymorphisms	131
Psychological	Identification of psychological markers and polymorphisms	132
Social	Identification of social markers and polymorphisms	133
Economic	Identification of economic markers and polymorphisms	134
Legal	Identification of legal markers and polymorphisms	135
Ethical	Identification of ethical markers and polymorphisms	136
Policy	Identification of policy markers and polymorphisms	137
Regulatory	Identification of regulatory markers and polymorphisms	138
Healthcare	Identification of healthcare markers and polymorphisms	139
Education	Identification of education markers and polymorphisms	140
Research	Identification of research markers and polymorphisms	141
Industry	Identification of industry markers and polymorphisms	142
Academia	Identification of academia markers and polymorphisms	143
Government	Identification of government markers and polymorphisms	144
Non-profit	Identification of non-profit markers and polymorphisms	145
Private	Identification of private markers and polymorphisms	146
Public	Identification of public markers and polymorphisms	147
Global	Identification of global markers and polymorphisms	148
Local	Identification of local markers and polymorphisms	149
National	Identification of national markers and polymorphisms	150
International	Identification of international markers and polymorphisms	151
Transnational	Identification of transnational markers and polymorphisms	152
Supranational	Identification of supranational markers and polymorphisms	153
Subnational	Identification of subnational markers and polymorphisms	154
Regional	Identification of regional markers and polymorphisms	155
Local	Identification of local markers and polymorphisms	156
Global	Identification of global markers and polymorphisms	157
Local	Identification of local markers and polymorphisms	158
National	Identification of national markers and polymorphisms	159
International	Identification of international markers and polymorphisms	160
Transnational	Identification of transnational markers and polymorphisms	161
Supranational	Identification of supranational markers and polymorphisms	162
Subnational	Identification of subnational markers and polymorphisms	163
Regional	Identification of regional markers and polymorphisms	164
Local	Identification of local markers and polymorphisms	165
Global	Identification of global markers and polymorphisms	166
Local	Identification of local markers and polymorphisms	167
National	Identification of national markers and polymorphisms	168
International	Identification of international markers and polymorphisms	169
Transnational	Identification of transnational markers and polymorphisms	170
Supranational	Identification of supranational markers and polymorphisms	171
Subnational	Identification of subnational markers and polymorphisms	172
Regional	Identification of regional markers and polymorphisms	173
Local	Identification of local markers and polymorphisms	174
Global	Identification of global markers and polymorphisms	175
Local	Identification of local markers and polymorphisms	176
National	Identification of national markers and polymorphisms	177
International	Identification of international markers and polymorphisms	178
Transnational	Identification of transnational markers and polymorphisms	179
Supranational	Identification of supranational markers and polymorphisms	180
Subnational	Identification of subnational markers and polymorphisms	181
Regional	Identification of regional markers and polymorphisms	182
Local	Identification of local markers and polymorphisms	183
Global	Identification of global markers and polymorphisms	184
Local	Identification of local markers and polymorphisms	185
National	Identification of national markers and polymorphisms	186
International	Identification of international markers and polymorphisms	187
Transnational	Identification of transnational markers and polymorphisms	188
Supranational	Identification of supranational markers and polymorphisms	189
Subnational	Identification of subnational markers and polymorphisms	190
Regional	Identification of regional markers and polymorphisms	191
Local	Identification of local markers and polymorphisms	192
Global	Identification of global markers and polymorphisms	193
Local	Identification of local markers and polymorphisms	194
National	Identification of national markers and polymorphisms	195
International	Identification of international markers and polymorphisms	196
Transnational	Identification of transnational markers and polymorphisms	197
Supranational	Identification of supranational markers and polymorphisms	198
Subnational	Identification of subnational markers and polymorphisms	199
Regional	Identification of regional markers and polymorphisms	200
Local	Identification of local markers and polymorphisms	201
Global	Identification of global markers and polymorphisms	202
Local	Identification of local markers and polymorphisms	203
National	Identification of national markers and polymorphisms	204
International	Identification of international markers and polymorphisms	205
Transnational	Identification of transnational markers and polymorphisms	206
Supranational	Identification of supranational markers and polymorphisms	207
Subnational	Identification of subnational markers and polymorphisms	208
Regional	Identification of regional markers and polymorphisms	209
Local	Identification of local markers and polymorphisms	210
Global	Identification of global markers and polymorphisms	211
Local	Identification of local markers and polymorphisms	212
National	Identification of national markers and polymorphisms	213
International	Identification of international markers and polymorphisms	214
Transnational	Identification of transnational markers and polymorphisms	215
Supranational	Identification of supranational markers and polymorphisms	216
Subnational	Identification of subnational markers and polymorphisms	217
Regional	Identification of regional markers and polymorphisms	218
Local	Identification of local markers and polymorphisms	219
Global	Identification of global markers and polymorphisms	220
Local	Identification of local markers and polymorphisms	221
National	Identification of national markers and polymorphisms	222
International	Identification of international markers and polymorphisms	223
Transnational	Identification of transnational markers and polymorphisms	224
Supranational	Identification of supranational markers and polymorphisms	225
Subnational	Identification of subnational markers and polymorphisms	226
Regional	Identification of regional markers and polymorphisms	227
Local	Identification of local markers and polymorphisms	228
Global	Identification of global markers and polymorphisms	229
Local	Identification of local markers and polymorphisms	230
National	Identification of national markers and polymorphisms	231
International	Identification of international markers and polymorphisms	232
Transnational	Identification of transnational markers and polymorphisms	233
Supranational	Identification of supranational markers and polymorphisms	234
Subnational	Identification of subnational markers and polymorphisms	235
Regional	Identification of regional markers and polymorphisms	236
Local	Identification of local markers and polymorphisms	237
Global	Identification of global markers and polymorphisms	238
Local	Identification of local markers and polymorphisms	239
National	Identification of national markers and polymorphisms	240
International	Identification of international markers and polymorphisms	241
Transnational	Identification of transnational markers and polymorphisms	242
Supranational	Identification of supranational markers and polymorphisms	243
Subnational	Identification of subnational markers and polymorphisms	244
Regional	Identification of regional markers and polymorphisms	245
Local	Identification of local markers and polymorphisms	246
Global	Identification of global markers and polymorphisms	247
Local	Identification of local markers and polymorphisms	248
National	Identification of national markers and polymorphisms	249
International	Identification of international markers and polymorphisms	250
Transnational	Identification of transnational markers and polymorphisms	251
Supranational	Identification of supranational markers and polymorphisms	252
Subnational	Identification of subnational markers and polymorphisms	253
Regional	Identification of regional markers and polymorphisms	254
Local	Identification of local markers and polymorphisms	255
Global	Identification of global markers and polymorphisms	256
Local	Identification of local markers and polymorphisms	257
National	Identification of national markers and polymorphisms	258
International	Identification of international markers and polymorphisms	259
Transnational	Identification of transnational markers and polymorphisms	260
Supranational	Identification of supranational markers and polymorphisms	261
Subnational	Identification of subnational markers and polymorphisms	262
Regional	Identification of regional markers and polymorphisms	263
Local	Identification of local markers and polymorphisms	264
Global	Identification of global markers and polymorphisms	265
Local	Identification of local markers and polymorphisms	266
National	Identification of national markers and polymorphisms	267
International	Identification of international markers and polymorphisms	268
Transnational	Identification of transnational markers and polymorphisms	269
Supranational	Identification of supranational markers and polymorphisms	270
Subnational	Identification of subnational markers and polymorphisms	271
Regional	Identification of regional markers and polymorphisms	272
Local	Identification of local markers and polymorphisms	273
Global	Identification of global markers and polymorphisms	274
Local	Identification of local markers and polymorphisms	275
National	Identification of national markers and polymorphisms	276
International	Identification of international markers and polymorphisms	277
Transnational	Identification of transnational markers and polymorphisms	278
Supranational	Identification of supranational markers and polymorphisms	279
Subnational	Identification of subnational markers and polymorphisms	280
Regional	Identification of regional markers and polymorphisms	281
Local	Identification of local markers and polymorphisms	282
Global	Identification of global markers and polymorphisms	283
Local	Identification of local markers and polymorphisms	284
National	Identification of national markers and polymorphisms	285
International	Identification of international markers and polymorphisms	286
Transnational	Identification of transnational markers and polymorphisms	287
Supranational	Identification of supranational markers and polymorphisms	288
Subnational	Identification of subnational markers and polymorphisms	289
Regional	Identification of regional markers and polymorphisms	290
Local	Identification of local markers and polymorphisms	291
Global	Identification of global markers and polymorphisms	292
Local	Identification of local markers and polymorphisms	293
National	Identification of national markers and polymorphisms	294
International	Identification of international markers and polymorphisms	295
Transnational	Identification of transnational markers and polymorphisms	296
Supranational	Identification of supranational markers and polymorphisms	297
Subnational	Identification of subnational markers and polymorphisms	298
Regional	Identification of regional markers and polymorphisms	299
Local	Identification of local markers and polymorphisms	300

Latest Research (27 Articles)

- Ioannidou D, Makri ES, Polyzos SA, Ntenti C, Agapakis D, Germanidis G, et al. An association study of the PNPLA3 I148M polymorphism (rs738409) with serum lipids in patients with dyslipidemia. *Explor Med.* 2023;4:16–22. <https://doi.org/10.37349/emed.2023.00121> [\[PDF\]](#)
- Almada-Correia I, Costa-Reis P, Sousa Guerreiro C, Eurico Fonseca J. Let's review the gut microbiota in systemic lupus erythematosus. *Explor Med.* 2022;3:540–60. <https://doi.org/10.37349/emed.2022.00112> [\[PDF\]](#)
- Kong F, Yan Z, Lan N, Wang P, Fan S, Yuan W. Construction and validation of gastric cancer diagnosis model based on machine learning. *Explor Med.* 2022;3:300–13. <https://doi.org/10.37349/emed.2022.00094> [\[PDF\]](#)
- Francica G. Pyogenic liver abscess: contrast-enhanced ultrasound allows morpho-evolutionary classification and guides personalized management. *Explor Med.* 2022;3:289–99. <https://doi.org/10.37349/emed.2022.00093> [\[PDF\]](#)
- Delladetsima K, Manesis E, Tiniakos D, Sakellariou S. Complex liver injury induced by combined Aloe Vera and vitamin A oral supplements, as assessed by histology and the updated RUCAM. *Explor Med.* 2022;3:181–7. <https://doi.org/10.37349/emed.2022.00084> [\[PDF\]](#)
- Romagnoli D. Elimination of hepatitis C virus infection in Europe: targeting the obstacles. *Explor Med.* 2022;3:71–6. <https://doi.org/10.37349/emed.2022.00075> [\[PDF\]](#)
- Zhang C, Liu S, Yang M. Functions of two distinct Kupffer cells in the liver. *Explor Med.* 2021;2:511–5. <https://doi.org/10.37349/emed.2021.00067> [\[PDF\]](#)
- Zhang C, Yang M. Molecular targets regulating endoplasmic reticulum-mitochondria crosstalk for NAFLD treatment. *Explor Med.* 2021;2:494–510. <https://doi.org/10.37349/emed.2021.00066> [\[PDF\]](#)
- Ali H. Future incidence and mortality of colorectal carcinoma in the United States: an updated overview of risk factors and preventative measures. *Explor Med.* 2021;2:455–67. <https://doi.org/10.37349/emed.2021.00063> [\[PDF\]](#)
- Lonardo A. Separating the apples from the oranges: from NAFLD heterogeneity to personalized medicine. *Explor Med.* 2021;2:435–442. <https://doi.org/10.37349/emed.2021.00061> [\[PDF\]](#)
- Akbar SMF, Al Mahtab M, Cesar Aguilar J, Uddin MH, Khan SI, Yoshida O, et al. Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical. *Explor Med.* 2021;2:392–409. <https://doi.org/10.37349/emed.2021.00058> [\[PDF\]](#)

12. Mantovani A, Beatrice G, Zusi C, Dalbeni A. Breastfeeding duration and reduced risk of NAFLD in midlife of parous women. *Explor Med.* 2021;2:378–81.
<https://doi.org/10.37349/emed.2021.00056> [PDF]
13. Cornacchia MG, Sangineto M, Villani R, Cavallone F, Di Gioia G, Cicciomessere P, et al. High prevalence of false positive SARS-CoV2 serology in a cohort of patients with liver autoimmune diseases. *Explor Med.* 2021;2:372–7.
<https://doi.org/10.37349/emed.2021.00055> [PDF]
14. Colucci A, Rocco MC, De Anseris AGE, Nazzaro L, Vajro P, Mandato C. Pediatric vs. adult NAFLD to MAFLD transition: a welcome but tangled path. *Explor Med.* 2021;2:333–42.
<https://doi.org/10.37349/emed.2021.00051> [PDF]
15. Di Vincenzo A, Russo L, Doroldi CG, Vettor R, Rossato M. Sex hormones abnormalities in non-alcoholic fatty liver disease: pathophysiological and clinical implications. *Explor Med.* 2021;2:311–23.
<https://doi.org/10.37349/emed.2021.00049> [PDF]
16. Baffy G. An engineered mayhem: YAP/TAZ mechanosignaling and hepatocarcinogenesis in NAFLD. *Explor Med.* 2021;2:305–10.
<https://doi.org/10.37349/emed.2021.00048> [PDF]
17. Delgado MG, Casu S, Montani M, Brunner F, Semmo N, Berzigotti A, et al. Hepatic manifestations of drug reaction with eosinophilia and systemic symptoms syndrome. *Explor Med.* 2021;2:122–34.
<https://doi.org/10.37349/emed.2021.00037> [PDF]
18. Lombardi R, Pisano G, Fargion S, Fracanzani AL. Cardiovascular involvement after liver transplantation: role of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Explor Med.* 2021;2:20–38.
<https://doi.org/10.37349/emed.2021.00030> [PDF]
19. Acierio C, Caturano A, Pafundi PC, Nevola R, Adinolfi LE, Sasso FC. Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin. *Explor Med.* 2020;1:287–306.
<https://doi.org/10.37349/emed.2020.00019> [PDF]
20. Rosato V, Masarone V, Aglitti A, Persico M. The diagnostic conundrum in non-alcoholic fatty liver disease. *Explor Med.* 2020;1:259–86.
<https://doi.org/10.37349/emed.2020.00018> [PDF]
21. Nassir F. Role of acetylation in nonalcoholic fatty liver disease: a focus on SIRT1 and SIRT3. *Explor Med.* 2020;1:248–58.
<https://doi.org/10.37349/emed.2020.00017> [PDF]
22. Meroni M, Longo M, Dongiovanni P. Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. *Explor Med.* 2020;1:218–43.
<https://doi.org/10.37349/emed.2020.00015> [PDF]
23. Mikolasevic I, Lukic A, Juric T, Klapan M, Madzar P, Krolo N, et al. Non-alcoholic fatty liver disease and transient elastography. *Explor Med.* 2020;1:205–17.
<https://doi.org/10.37349/emed.2020.00014> [PDF]
24. Doulberis M, Papadimitriou K, Papaefthymiou A, Jannis Kountouras J, Polyzos SA. The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis. *Explor Med.* 2020;1:170–83.

<https://doi.org/10.37349/emed.2020.00012>

[PDF]

25. Ryou M, Stylopoulos N, Baffy G. Nonalcoholic fatty liver disease and portal hypertension. Explor Med. 2020;1:149–69.

<https://doi.org/10.37349/emed.2020.00011>

[PDF]

26. Lonardo A, Ballestri S. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Explor Med. 2020;1:85–107.

<https://doi.org/10.37349/emed.2020.00007>

[PDF]

27. Salvoza NC, Giraudi PJ, Tiribelli C, Rosso N. Sex differences in non-alcoholic fatty liver disease: hints for future management of the disease. Explor Med. 2020;1:51–74.

<https://doi.org/10.37349/emed.2020.00005>

[PDF]

Genetics & Genome Biology, Computational Biomedicine

Featured

Top Download

[Neuropsychological test validation of speech markers of cognitive impairment in the Framingham Cognitive Aging Cohort](#)

Larry Zhang, Anthony Ngo, Jason A. Thomas, Hannah A. Burkhardt, Carolyn M. Parsey, Rhoda Au, Reza Hosseini Ghomi


[PDF](#)

Top Read

[Proof of concept: digital clock drawing behaviors prior to transcatheter aortic valve replacement may predict length of hospital stay and cost of care](#)

Margaret Ellenora Wiggins, Catherine Dion, Erin Formanski, Anis Davoudi, Shawna Amini, Kenneth M. Heilman, Dana Penney, Randall Davis, Cynthia W. Garvan, George J. Arnaoutakis, Patrick Tighe, David J. Libon, Catherine C. Price

[PDF](#) View: 1940



Latest Research (18 Articles)

1. Vervoort L, Vermeesch JR. Low copy repeats in the genome: from neglected to respected. Explor Med. 2023;4:166-75.

<https://doi.org/10.37349/emed.2023.00131>

[PDF]

2. Sato H, Hara T, Otsuka C, Arao Y, Tsuji Y, Hamano Y, et al. m6 RNA methylation: an emerging common target in the immune response to cancer and severe acute respiratory

- syndrome-coronavirus-2 infection. *Explor Med.* 2023;4:107–14.
<https://doi.org/10.37349/emed.2023.00127> [PDF]
3. Sobhon P, Savedvanich G, Weerakiet S. Oxidative stress, inflammation, dysfunctional redox homeostasis and autophagy cause age-associated diseases. *Explor Med.* 2023;4:45–70.
<https://doi.org/10.37349/emed.2023.00124> [PDF]
4. Maynard T, Appleman E, Cronin-Golomb A, Nearing S. Objective measurement of sleep by smartphone application: comparison with actigraphy and relation to self-reported sleep. *Explor Med.* 2021;2:382–91.
<https://doi.org/10.37349/emed.2021.00057> [PDF]
5. Thomas RJ, Kim H, Maillard P, DeCarli CS, Heckman EJ, Karjadi C, et al. Digital sleep measures and white matter health in the Framingham Heart Study. *Explor Med.* 2021;2:253–67.
<https://doi.org/10.37349/emed.2021.00045> [PDF]
6. Zhang L, Ngo A, Thomas JA, Burkhardt HA, Parsey CM, Au R, et al. Neuropsychological test validation of speech markers of cognitive impairment in the Framingham Cognitive Aging Cohort. *Explor Med.* 2021;2:232–52.
<https://doi.org/10.37349/emed.2021.00044> [PDF]
7. Wiggins ME, Dion C, Formanski E, Davoudi A, Amini S, Heilman KM, et al. Proof of concept: digital clock drawing behaviors prior to transcatheter aortic valve replacement may predict length of hospital stay and cost of care. *Explor Med.* 2020;2:110–21.
<https://doi.org/10.37349/emed.2021.00036> [PDF]
8. Emrani S, Lamar M, Price CC, Baliga S, Wasserman V, Matusz E, et al. Assessing the capacity for mental manipulation in patients with statically-determined mild cognitive impairment using digital technology. *Explor Med.* 2021;2:86–97.
<https://doi.org/10.37349/emed.2021.00034> [PDF]
9. Fu R, Mitsakakis N, Chaiton M. A machine learning approach to identify correlates of current e-cigarette use in Canada. *Explor Med.* 2021;2:74–85.
<https://doi.org/10.37349/emed.2021.00033> [PDF]
10. Sherva R, Zhu C, Wetherill L, Edenberg HJ, Johnson E, Degenhardt L, et al. Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes. *Explor Med.* 2021;2:60–73.
<https://doi.org/10.37349/emed.2021.00032> [PDF]
11. Lin H, Karjadi C, Ang TFA, Prajakta J, McManus C, Alhanai TW, et al. Identification of digital voice biomarkers for cognitive health. *Explor Med.* 2020;1:406–17.
<https://doi.org/10.37349/emed.2020.00028> [PDF]
12. Ye S, Ko B, Phi H, Sun K, Eagleman DM, Flores B, et al. Detection of mild traumatic brain injury in pediatric populations using BrainCheck, a tablet-based cognitive testing software: a preliminary study. *Explor Med.* 2020;1:396–405.
<https://doi.org/10.37349/emed.2020.00027> [PDF]
13. Qorri B, Tsay M, Agrawal A, Au R, Geraci J. Using machine intelligence to uncover Alzheimer’s disease progression heterogeneity. *Explor Med.* 2020;1:377–95.
<https://doi.org/10.37349/emed.2020.00026> [PDF]
14. Bjorklund NL, Fillit H, Malzbender K, Purushothama S, Kourtis L. The need for a harmonized speech dataset for Alzheimer’s disease biomarker development. *Explor Med.* 2020;1:359–63.
<https://doi.org/10.37349/emed.2020.00024> [PDF]

15. Dharmadhikari B, Patra S, Patra P. High-performance computing will assist experiments in recovery from COVID-19. *Explor Med.* 2020;1:355–8.
<https://doi.org/10.37349/emed.2020.00023> [PDF]
16. Quandt LM, Raji CA. Going against the norm: validation of a novel alternative to brain SPECT normative datasets. *Explor Med.* 2020;1:331–54.
<https://doi.org/10.37349/emed.2020.00022> [PDF]
17. Wachman EM, Wang A, Isley BC, Boateng J, Beierle JA, Hansbury A, et al. Placental OPRM1 DNA methylation and associations with neonatal opioid withdrawal syndrome, a pilot study. *Explor Med.* 2020;1:124–35.
<https://doi.org/10.37349/emed.2020.00009> [PDF]
18. Cox JW, Sherva RM, Lunetta KL, Saitz R, Kon M, Kranzler HR, et al. Identifying factors associated with opioid cessation in a biracial sample using machine learning. *Explor Med.* 2020;1:27–41.
<https://doi.org/10.37349/emed.2020.00003> [PDF]

Microbiology, Immunology & Infectious Disease


Featured

Top Read

[The gut microbiome and the immune system](#)

Tenzin Choden, Nathaniel Aviv Cohen

[PDF](#)



Latest Research (14 Articles)

1. Silva MG, Inserra F, Mariani J, Antonietti L, Nuñez M, Tajer C, et al. Mechanistic approaching study in COVID-19 patients treated with high doses of vitamin D. *Explor Med.* 2023;4:246 – 53.
<https://doi.org/10.37349/emed.2023.00137> [PDF]
2. Cundra LB, Vallabhaneni M, Saadeh M, Houston KV, Yoo BS, D’ Souza S, et al. Immunomodulation strategies against COVID-19 evidence: key nutrients and dietary approaches. *Explor Med.* 2023;4:189-206.
<https://doi.org/10.37349/emed.2023.00133> [PDF]
3. Houston KV, Patel A, Saadeh M, Vargas A, Vilela Sangay AR, D’ Souza SM, et al. Gastrointestinal microbiome and coronavirus disease: evidence of a bidirectional association. *Explor Med.* 2023;4:157 – 65.
<https://doi.org/10.37349/emed.2023.00130> [PDF]
4. Singh D, Singh A, Chawla PA. An overview of current strategies and future prospects in drug repurposing in tuberculosis. *Explor Med.* 2023;4:71–84.
<https://doi.org/10.37349/emed.2023.00125> [PDF]
5. Chaurasiya A, Shome A, Chawla PA. Molecular docking analysis of peptide-based antiviral agents against SARS-CoV-2 main protease: an approach towards drug repurposing. *Explor Med.*

2023;4:33–44.

<https://doi.org/10.37349/emed.2023.00123>

[PDF]

6. Choueiry R, Faddoul J, Najjar J, Ghorra C, Mansour J, Safi N, et al. An unusual presentation of Whipple's disease: adenopathies, polyarthralgia and dermatomyositis-like symptoms. *Explor Med.* 2022;3:561–70.
<https://doi.org/10.37349/emed.2022.00113> [PDF]
7. Mudenkattil S, Girigoswami A, Jayaprakash T, Girigoswami K. Development of nanobiosensors for human immunodeficiency virus detection—a mini review. *Explor Med.* 2022;3:479–93.
<https://doi.org/10.37349/emed.2022.00109> [PDF]
8. Ikeda Y, Taniguchi K, Yoshikawa S, Sawamura H, Tsuji A, Matsuda S. A budding concept with certain microbiota, anti-proliferative family proteins, and engram theory for the innovative treatment of colon cancer. *Explor Med.* 2022;3:468–78.
<https://doi.org/10.37349/emed.2022.00108> [PDF]
9. Okay S. Involvement of retroelements in the autoimmune response in humans. *Explor Med.* 2022;3:280–8.
<https://doi.org/10.37349/emed.2022.00092> [PDF]
10. Chichlowski M, Cotter J, Fawkes N, Pandey N. Feed your microbiome and improve sleep, stress resilience, and cognition. *Explor Med.* 2022;3:331–44.
<https://doi.org/10.37349/emed.2022.00097> [PDF]
11. Merra G, Capacci A, De Lorenzo A, Di Renzo L, Gualtieri P, Frank G, et al. Does our microbiota eat with or without gluten? *Explor Med.* 2022;3:275–9.
<https://doi.org/10.37349/emed.2022.00091> [PDF]
12. Rubio-Casillas A, Gupta RC, Redwan EM, Uversky VN, Badierah R. Early taurine administration as a means for halting the cytokine storm progression in COVID-19 patients. *Explor Med.* 2022;3:234–48.
<https://doi.org/10.37349/emed.2022.00088> [PDF]
13. Choden T, Cohen NA. The gut microbiome and the immune system. *Explor Med.* 2022;3:219–33.
<https://doi.org/10.37349/emed.2022.00087> [PDF]
14. Budak GG, Özkan S, Budak M, Şeker T, Meryemoglu B, Miran ŞS, et al. Preclinical toxicity test results of a new antiviral–immune-modulator compound consisting of flavonoid molecules (COVID-19 clinical trial preliminary data). *Explor Med.* 2022;3:1–21.
<https://doi.org/10.37349/emed.2022.00071> [PDF]

Neuroscience & Neuropsychiatric Disorders


Featured

Editor's Pick

[Angiotensin-\(1-7\) and Mas receptor in the brain](#)

Natalia L. Rukavina Mikusic, Angélica M. Pineda, Mariela M. Gironacci

[PDF](#)



Latest Research (5 Articles)

1. Choudhary S, Kaur R, Waziri A, Garg A, Kadian R, Alam MS. N-type calcium channel blockers: a new approach towards the treatment of chronic neuropathic pain. *Explor Med.* 2023;4:85-106. <https://doi.org/10.37349/emed.2023.00126> [\[PDF\]](#)
2. Ali H, Patel P, Dhillon R, Sarfraz S, Poola S, Smith-Martinez L, et al. Disparities and trends in suicidal ideations for inflammatory bowel disease hospitalizations: a decade-long national database analysis. *Explor Med.* 2023;4:23 – 32. <https://doi.org/10.37349/emed.2023.00122> [\[PDF\]](#)
3. Yadav M, Dahiya M, Dagar J, Singh N, Sharma N, Rawat N, et al. Role of mitochondria in brain functions and related disorders. *Explor Med.* 2022;3:494-515. <https://doi.org/10.37349/emed.2022.00110> [\[PDF\]](#)
4. Di Agostino S, Costanzo AAC, Andreone P, Maurantonio M. Central pontine myelinolysis secondary to glycemic variability in type 1 diabetes: a case report and a systematic review of the literature. *Explor Med.* 2021;2:324–332. <https://doi.org/10.37349/emed.2021.00050> [\[PDF\]](#)
5. Rukavina Mikusic NL, Pineda AM, Gironacci MM. Angiotensin-(1-7) and Mas receptor in the brain. *Explor Med.* 2021;2:268–93. <https://doi.org/10.37349/emed.2021.00046> [\[PDF\]](#)

Urology & Nephrology


Featured

Top Read

[Angiotensin peptides in the regulation of adrenal cortical function](#)

Gian Paolo Rossi, Livia Lenzini, Brasilina Caroccia, Giacomo Rossitto, Teresa Maria Seccia

[PDF](#)




Editor's Pick

[Hyperuricemia—a serious complication among patients with chronic kidney disease: a systematic review and meta-analysis](#)

Ishfaq Rashid, Pooja Katravath, Pramila Tiwari, Sanjay D'Cruz, Shivani Jaswal, Gautam Sahu

[PDF](#)




Rising Star

[Angiotensin-\(3-4\) modulates the overweight- and undernutrition-induced ACE2 downregulation in renal proximal tubule cells: implications for COVID-19?](#)

Rafael Luzes, Humberto Muzi-Filho, Amaury Pereira-Acácio, Thuany Crisóstomo, Adalberto Vieyra

[PDF](#)



Latest Research (8 Articles)

- Shen G, He H, Wang Z, Qiu H, Zhu Y, Zheng D, et al. Predictive value of SII and sd-LDL for contrast-induced acute kidney injury in STEMI patients undergoing percutaneous coronary intervention. *Explor Med*. 2022;3:571–82. <https://doi.org/10.37349/emed.2022.00114> [\[PDF\]](#)
- Choueiri R, Faddoul J, Ghorra C, Al Najjar J, Akiki BB, Boustany S, et al. A case report: 19-year-old male diagnosed with C1q nephropathy requiring renal replacement therapy. *Explor Med*. 2022;3:386–92. <https://doi.org/10.37349/emed.2022.00101> [\[PDF\]](#)
- Malaki M. Adenine-rich diet: a potential mechanism for renal fibrosis progression. *Explor Med*. 2022;3:314–6. <https://doi.org/10.37349/emed.2022.00095> [\[PDF\]](#)
- Zhao YY. Recent advances of gut microbiota in chronic kidney disease patients. *Explor Med*. 2022;3:260–74. <https://doi.org/10.37349/emed.2022.00090> [\[PDF\]](#)
- Rashid I, Katravath P, Tiwari P, D'Cruz S, Jaswal S, Sahu G. Hyperuricemia—a serious complication among patients with chronic kidney disease: a systematic review and meta-analysis. *Explor Med*. 2022;3:249–59. <https://doi.org/10.37349/emed.2022.00089> [\[PDF\]](#)
- Rossi GP, Lenzini L, Caroccia B, Rossitto G, Seccia TM. Angiotensin peptides in the regulation of adrenal cortical function. *Explor Med*. 2021;2:294–304. <https://doi.org/10.37349/emed.2021.00047> [\[PDF\]](#)
- Luzes R, Muzi-Filho H, Pereira-Acácio A, Crisóstomo T, Vieyra A. Angiotensin-(3-4) modulates the overweight- and undernutrition-induced ACE2 downregulation in renal proximal tubule cells: implications for COVID-19? *Explor Med*. 2021;2:135–45. <https://doi.org/10.37349/emed.2021.00038> [\[PDF\]](#)
- Mantovani A, Zusi C. PNPLA3 gene and kidney disease. *Explor Med*. 2020;42–50.

<https://doi.org/10.37349/emed.2020.00004>

[PDF]

Women's Health


Featured

Top Read

[The potential anti-cancer effects of melatonin on breast cancer](#)

Naba Kumar Das, Saptadip Samanta

[PDF](#) View: 4241



Latest Research (4 Articles)

1. Misra P, Gopinath R, Naredi N, Kandi SM, Raj S, Vashum Y. Serum levels of ceruloplasmin and magnesium in polycystic ovarian syndrome: a cross sectional study. *Explor Med.* 2023;4:286-98. <https://doi.org/10.37349/emed.2023.00140> [PDF]
2. Das NK, Samanta S. The potential anti-cancer effects of melatonin on breast cancer. *Explor Med.* 2022;3:112-27. <https://doi.org/10.37349/emed.2022.00078> [PDF]
3. Reeve KE, Deer E, Amaral LM, Cornelius DC, Herrock O, Harmon AC, et al. Placental CD4+ T cells from preeclamptic patients cause autoantibodies to the angiotensin II type I receptor and hypertension in a pregnant rat model of preeclampsia. *Explor Med.* 2022;3:99-111. <https://doi.org/10.37349/emed.2022.00077> [PDF]
4. Lao TT. Obstetric implications of maternal chronic hepatitis B virus infection. *Explor Med.* 2021;2:468-82. <https://doi.org/10.37349/emed.2021.00064> [PDF]

Others


Featured

Editor's Pick

[Paradoxical role of reactive oxygen species in bone remodelling: implications in osteoporosis and possible nanotherapeutic interventions](#)

Largee Biswas, Karishma Niveria, Anita Kamra Verma

[PDF](#)




Rising Star

Downhill esophageal varices: a systematic review of the case reports

Hassam Ali, Rahul Pamarthy, Nicole Leigh Bolick,
Eslam Ali, Swathi Paleti, Devika Kapuria

[PDF](#)



Latest Research (19 Articles)

1. Santonocito S, Ferlito S, Polizzi A, Ronsivalle V, Reitano G, Lo Giudice A, et al. Impact exerted by scaffolds and biomaterials in periodontal bone and tissue regeneration engineering: new challenges and perspectives for disease treatment. *Explor Med.* 2023;4:215-34.
<https://doi.org/10.37349/emed.2023.00135> [\[PDF\]](#)
2. Annarumma G, Spinelli A, Serio A, Di Fraia T, Gallinoro CM, Caoduro L, et al. Forward head posture and neck disability: what is the effect on lung function? *Explor Med.* 2023;4:207-14.
<https://doi.org/10.37349/emed.2023.00134> [\[PDF\]](#)
3. Parveen R, Samal M, Nafis, Mukhtar HM, Ahmad S. Development of solid lipid nanoparticle gel for transdermal delivery system of chaulmoogra oil. *Explor Med.* 2023;4:176 – 88.
<https://doi.org/10.37349/emed.2023.00132> [\[PDF\]](#)
4. Sobhon P, Savedvanich G, Weerakiet S. Oxidative stress and inflammation: the root causes of aging. *Explor Med.* 2023;4:127 – 56.
<https://doi.org/10.37349/emed.2023.00129> [\[PDF\]](#)
5. Balyen L. Ultra-widefield imaging technologies in the peripheral retinal pathologies. *Explor Med.* 2023;4:1–2.
<https://doi.org/10.37349/emed.2023.00119> [\[PDF\]](#)
6. Alam T. Quality by design based development of nanostructured lipid carrier: a risk based approach. *Explor Med.* 2022;3:617–38.
<https://doi.org/10.37349/emed.2022.00118> [\[PDF\]](#)
7. Cruz RYMS, Arévalo SV, Rashid A, Jara MRA, Prado MSA. Antioxidant and photoprotective potential of Polypodium leucotomos. *Explor Med.* 2022;3:607–16.
<https://doi.org/10.37349/emed.2022.00117> [\[PDF\]](#)
8. Mall SK, Yadav T, Waziri A, Alam MS. Treatment opportunities with *Fernandoa adenophylla* and recent novel approaches for natural medicinal phytochemicals as a drug delivery system. *Explor Med.* 2022;3:516–39.
<https://doi.org/10.37349/emed.2022.00111> [\[PDF\]](#)
9. Seyyedi SA, Taram S, Heydari M, Valizadeh R. Efficacy of low-level laser therapy in oral mucosal surgical wound healing: a systematic review and meta-analysis. *Explor Med.* 2022;3:451–60.
<https://doi.org/10.37349/emed.2022.00106> [\[PDF\]](#)
10. Tanni B, Voundi EV, Omigbodun A, Aimakhu CO. Seminal fructose and citric acid concentrations relative to sperm parameters among men for fertility evaluation in Yaoundé, Cameroon. *Explor Med.* 2022;3:443–50.
<https://doi.org/10.37349/emed.2022.00105> [\[PDF\]](#)
11. Biswas L, Niveria K, Verma AK. Paradoxical role of reactive oxygen species in bone

remodelling: implications in osteoporosis and possible nanotherapeutic interventions. *Explor Med.* 2022;3:393–413.

<https://doi.org/10.37349/emed.2022.00102>

[PDF]

12. Shah NH, Vaghela JN, Pandya PM, Shah YN. Mathematical model for transmission of Chlamydia due to sexual activity and unhygienic environment. *Explor Med.* 2022;3:375–85.
<https://doi.org/10.37349/emed.2022.00100> [PDF]
13. Nguyen LTH. Signaling pathways and targets of natural products in psoriasis treatment. *Explor Med.* 2022;3:345–67.
<https://doi.org/10.37349/emed.2022.00098> [PDF]
14. Ali H, Pamorthy R, Bolick NL, Ali E, Paleti S, Kapuria D. Downhill esophageal varices: a systematic review of the case reports. *Explor Med.* 2022;3:317–30.
<https://doi.org/10.37349/emed.2022.00096> [PDF]
15. Hicks PM, Siedlecki A, Haaland B, Owen LA, Au E, Feehan M, et al. A global genetic epidemiological review of pseudoexfoliation syndrome. *Explor Med.* 2021;2:527–43.
<https://doi.org/10.37349/emed.2021.00069> [PDF]
16. Ly A, Pelletier S, Dionne CE. Cross-cultural adaptation of Delphi definitions of low back pain prevalence in French (Delphi DOLBaPP-F). *Explor Med.* 2021;2:483–93.
<https://doi.org/10.37349/emed.2021.00065> [PDF]
17. Ali H, Naseer M. Submucosal esophageal hematomas in a critically ill patient on anticoagulation. *Explor Med.* 2021;2:343–7.
<https://doi.org/10.37349/emed.2021.00052> [PDF]
18. de la Fuente J, Bedia J, Gortázar C. Visual communication and learning from COVID-19 to advance preparedness for pandemics. *Explor Med.* 2020;1:244–7.
<https://doi.org/10.37349/emed.2020.00016> [PDF]
19. Carroll L, Owen LA. Current evidence and outcomes for retinopathy of prematurity prevention: insights into novel maternal and placental disease contributions. *Explor Med.* 2020:4–26.
<https://doi.org/10.37349/emed.2020.00002> [PDF]